Founded in 2013 by Jonathan Medved, OurCrowd pioneered a model that democratised venture capital for the affluent: an equity-crowdfunding platform where accredited investors co-invest — at the same terms — alongside the firm's professional investment team. Rated by PitchBook as the most active venture investor in Israel, the platform reported $1.4 billion in committed funding, 200 portfolio companies and 20 venture funds, backed by a membership of more than 41,000 accredited and institutional investors, family offices and VC partners across 183 countries.
The thesis spans sectors and stages: from seed and Series A through late-stage and pre-IPO companies, diversified across geographies. What investors — and founders — buy into is the selection machine. OurCrowd vets and selects companies, invests its own capital first, manages each investment as the general partner, and then opens the deal to its membership. The minimum investment is $10,000 per deal, and members pick the deals they want exposure to, building a diversified venture portfolio alongside trusted funds.
The portfolio includes mPrest, Enverid, Surgical Theater, BioCatch, Zebra, Consumer Physics (SCiO) and Borro, and the firm's first portfolio company to complete an IPO was ReWalk Robotics on NASDAQ. Exit outcomes for portfolio companies include acquisitions by Uber, Canon, Oracle, Nike, Intel and Microsoft — a roster that signals the platform's ability to surface companies the world's largest buyers want.
For founders, the value is layered. Beyond capital, OurCrowd provides mentorship, assigns industry-expert advisors, takes board seats and mobilises its global investor network for follow-on rounds and growth. The firm also runs dedicated programmes: Labs/02, its Jerusalem-based incubator built with the Israel Innovation Authority and Reliance Industries; the OurCrowd Global Investor Summit, one of the startup world's largest investor gatherings; and specialist vehicles such as the $100 million Pandemic Innovation Fund, launched for accredited and institutional investors to back pandemic-era innovation.
Credits and perks are not published as a standing catalogue; the firm's founder-facing offering centres on mentorship, board-level guidance and multinational partnership access. For Indian and global founders, the practical takeaway is simple: OurCrowd offers a second route into Israeli venture — not just capital, but distribution into a network of tens of thousands of investors who actively open doors.
Why it matters for founders
OurCrowd gives founders access to a unique dual asset: institutional-grade vetting plus a retail-scale network of 41,000+ investors who co-invest and open doors. It is not a lead VC in the traditional sense — founders should pitch it as capital-plus-distribution. And for accredited readers of Nora Fund, it remains one of the few credible on-ramps into Israeli venture at a $10,000 minimum.